SIGN: a Phase II, open-label, randomized study comparing gefitinib (IRESSA) with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

被引：1
|
作者：
Cufer, T
Vrdoljak, E
机构：
[1] Clin Hosp Split, Split, Croatia
[2] Inst Oncol, Ljubljana, Slovenia
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80403-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S87 / S87
页数：1
相关论文
共 50 条
  • [41] Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)
    Shi, Yuankai
    Wu, Lin
    Yu, Xinmin
    Xing, Puyuan
    Wang, Yan
    Zhou, Jianying
    Wang, Airong
    Shi, Jianhua
    Hu, Yi
    Wang, Ziping
    An, Guangyu
    Fang, Yong
    Sun, Sanyuan
    Zhou, Caicun
    Wang, Changli
    Ye, Feng
    Li, Xingya
    Wang, Junye
    Wang, Mengzhao
    Liu, Yunpeng
    Zhao, Yanqiu
    Yuan, Ying
    Feng, Jifeng
    Chen, Zhendong
    Shi, Jindong
    Sun, Tao
    Wu, Gang
    Shu, Yongqian
    Guo, Qisen
    Zhang, Yi
    Song, Yong
    Zhang, Shucai
    Chen, Yuan
    Li, Wei
    Niu, Hongrui
    Hu, Wenwei
    Wang, Lijun
    Huang, Jianan
    Zhang, Yang
    Cheng, Ying
    Wu, Zhengdong
    Peng, Bo
    Sun, Jiya
    Mancao, Christoph
    Wang, Yanqi
    Sun, Luyao
    CANCER COMMUNICATIONS, 2022, 42 (12) : 1314 - 1330
  • [42] A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer
    Yoshioka, H.
    Katakami, N.
    Okamoto, H.
    Iwamoto, Y.
    Seto, T.
    Takahashi, T.
    Sunaga, N.
    Kudoh, S.
    Chikamori, K.
    Harada, M.
    Tanaka, H.
    Saito, H.
    Saka, H.
    Takeda, K.
    Nogami, N.
    Masuda, N.
    Harada, T.
    Kitagawa, H.
    Horio, H.
    Yamanaka, T.
    Fukuoka, M.
    Yamamoto, N.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2017, 28 (02) : 285 - 291
  • [43] Weekly docetaxel as second-line therapy in non-small cell lung cancer: a phase II study
    Rossi, D
    Graziano, F
    Ugolini, M
    Dennetta, D
    Alessandroni, P
    Catalano, V
    Giordani, P
    Fedeli, SL
    Fedeli, A
    Catalano, G
    TUMORI JOURNAL, 2004, 90 (01): : 50 - 53
  • [44] Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer
    Brell, Joanna M.
    Matin, Khalid
    Evans, Terry
    Volkin, Robert L.
    Kiefer, Gauri J.
    Schlesselman, James J.
    Dranko, Shelley
    Rath, Linda
    Schmotzer, Amy
    Lenzner, Diana
    Ramanathan, Ramesh K.
    ONCOLOGY, 2009, 76 (04) : 270 - 274
  • [45] Docetaxel as second-line chemotherapy for non-small-cell lung cancer
    Roila, F
    Del Favero, A
    Ballatori, E
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) : 3738 - 3738
  • [46] A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer
    Stinchcombe, Thomas E.
    Buzkova, Petra
    Choksi, Janak
    Taylor, Mark
    Bakri, Kamal
    Gillenwater, Heidi
    Tynan, Maureen
    Mears, Andrea
    Jones, Paul E.
    Socinski, Mark A.
    LUNG CANCER, 2006, 52 (03) : 305 - 311
  • [47] Phase II study of cabazitaxel as second-line therapy in stage IV non-small cell lung cancer (NSCLC).
    Das, Devika
    Robert, Francisco
    Bordoni, Rodolfo
    Grant, Stefan C.
    Saleh, Mansoor N.
    Reddy, Vishnu
    Jerome, Mary
    Miley, Debi
    Singh, Karen P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] Comparison of erlotinib (Tarceva™) versus gefitinib (Iressa®) as the second line therapy for the treatment of advanced non-small cell lung cancer patients: a randomized phase II trial
    Uhm, Ji Eun
    Sun, Jong Mu
    Lee, Soo Hyeon
    Kong, Jee Hyun
    Yun, Jin A.
    Lee, Sang Mi
    Lee, Jeeyun
    Park, Yeon Hee
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S292 - S292
  • [49] An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer
    Scagliotti, Giorgio V.
    Felip, Enriqueta
    Besse, Benjamin
    von Pawel, Joachim
    Mellemgaard, Anders
    Reck, Martin
    Bosquee, Lionel
    Chouaid, Christos
    Lianes-Barragan, Pilar
    Paul, Elaine M.
    Ruiz-Soto, Rodrigo
    Sigal, Entisar
    Ottesen, Lone H.
    LeChevalier, Thierry
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (12) : 1529 - 1537
  • [50] A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer
    Jones, Suzanne
    Thompson, Dana
    Barton, John
    Patton, Jeff
    Shipley, Dianna
    Greco, E. Anthony
    Spigel, David
    Infante, Jeff
    Burris, Howard A., III
    CLINICAL LUNG CANCER, 2008, 9 (03) : 154 - 159
12345